Correction to: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer-An NCDB Analysis (2004-2016)

Ann Surg Oncol. 2021 Dec;28(Suppl 3):888. doi: 10.1245/s10434-021-10403-5.

Macy M Goldbach¹, Laura Burkbauer², Tina Bharani², Austin D Williams³, Luke Keele⁴, Jami Rothman^{2

5}, Rachel Jankowitz⁵, Julia C Tchou^{1

6}

¹ Division of Endocrine and Oncologic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. [email protected].
² Division of Endocrine and Oncologic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Surgery, Lankenau Medical Center, Wynnewood, PA, USA.
⁴ Division of Epidemiology and Biostatistics, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁵ Rena Rowan Breast Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Rena Rowan Breast Center, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. [email protected].

No abstract available

Publication types